Plné znění - 2/2008 Sb. m. s.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 16. xxxxxxxxx 2007 xxxx xxxxxxxxxx xxxxxxxxx XXXXXX, xxxxxxxxxxx Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx¹⁾, xxxxxxxx xxxxxxxxx xxxxxx xxxxx Přílohy I - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx.

Xxxxxxx X vstoupila x xxxxxxxx v xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2008 x xxxxx xxxx vstoupila x xxxxxxxx x xxx Xxxxxx republiku. Xxxx xxxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx Xxxxxxx X Xxxxxxxxxxx xxxxxx proti xxxxxxx ve xxxxxx xx znění xxx xxx 2007, vyhlášená xxx x. 59/2007 Xx. x. s.

Xxxxxxxx xxxxx Přílohy X x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.

X1. ANABOLICKÉ LÁTKY

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (AAS):

x. Xxxxxxxx * XXX, zahrnující:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (19-xxxxxxxxxxxxxxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-metyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; furazabol (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx); methyl-1-testosteron (17β-xxxxxxx-17α-xxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); norboleton; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; prostanozol ([3,2-x]xxxxxxx-5α-xxxxxxxxxxxxxx-17β-xxxxxxxxxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); xxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx ** XXX:

Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA), xxxxxxxxxxx x následující xxxxxxxxxx x xxxxxxx:

5α-xxxxxxxxx-3α,17α-xxxx xxxxxxx-5-xx-3β,17α-xxxx

5α-xxxxxxxxx-3α,17β-xxxx 4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)

5α-xxxxxxxxx-3β,17α-xxxx 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)

5α-androstan-3β,17β-diol epi-dihydrotestosteron

androst-4-en-3α,17α-diol 3α-hydroxy-5αandrostan-17-on

xxxxxxx-4-xx-3α,17β-xxxx 3β-xxxxxxx-5αxxxxxxxxx-17-xx

androst-5-en-3β,17α-diol 19-norandrosteron

xxxxxxx-5-xx-3α,17α-xxxx 19-xxxxxxxxxxxxxxxxx

androst-5-en-3α,17β-diol

X xxxxxxxxx, kdy xxxx xxxx xxxxxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxx, xxxx xx mít xx xx, že Xxxxxx xxxxxxxx xxxx Xxxxxxxxx xxxxx x xxxx hlášen xxxxxxxxx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxx xx koncentrace Xxxxxxxx xxxxx nebo xxxxxx metabolitů xxxx xxxxxxxxxxx x/xxxx xxxx xx jakýkoli xxxx xxxxxxxxx poměr xx Xxxxxx Sportovce významně xxxxxxxxx xx rozmezí xxxxxx, xxxxx se xxxxxxxx xxxxxxxxx x xxxx tak, xx xxxxxxxxxx xxxxxxxx endogenní xxxxxxxx. Xxxxxx xx xxx za to, xx Xxxxxx obsahuje Xxxxxxxxx xxxxx v xxxxxxx případě, pokud Xxxxxxxxx prokáže, xx xx xxxxxxxxxxx Xxxxxxxx xxxxx xxxx xxxxxx xxxxxxxxxx nebo xxxxxxxxxx x/xxxx xxxxxxxxx xxxxx xx Xxxxxx Sportovce xxxxxxxx fyziologickým xxxx xxxxxxxxxxxx xxxxxx.

Xxxx xx xxx xx xx, že Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx a xxxxxxxxx xxxxxxx Xxxxxxxxx laboratorní xxxxx ve všech xxxxxxxxx x xxx xxxxxxxxx xxxxxxxxxxx, xxxxx xxx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxx, že xx Xxxxxxxx xxxxx xxxxxxxxxx xxxxxx. V xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

Xxxx xx xxxxxxx xxxxxxxx xxxxxxx xxxxxxxx neodchylují xx xxxxxxx xxxxxx, které xx normálně xxxxxxxxx x lidí x xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. XXXX) xxxxxxxxxxx exogenní původ Xxxxxxxx xxxxx, xxx xxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky, jako xxxx. porovnání s xxxxxxxxxxx referenčními steroidními xxxxxxx, nebo když xxxxxxxxx xxxxxxxxx poměr X/X xxxxx xxx xxxxx (4) xx xxxxx (1) x xxxxx spolehlivá xxxxxxxxxx xxxxxx (např. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx xxxxx, xxxxxxx příslušná Xxxxxxxxxxxxx xxxxxxxxxx další xxxxxxx porovnáním výsledků xxxxxxxxxx xxxxx nebo xxxxxxxxxx následných xxxxx.

Xx-xx xxxxxxxxxx takové xxxxx xxxxxxx, pak xxxxxxxx bude xxxxxxxxxx xxxxxx xxxx xxxxxxxxx x ne xxxx xxxxxxxxx. Pokud xxxxxxxxx xxxxxxx, xx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. IRMS) xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxxxx xxxxxxxx xxxxx šetření, x xxxx xx xxx xx to, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx. Pokud xxxxxx xxxxxxx spolehlivá xxxxxxxxxx xxxxxx (např. XXXX) x nejsou x xxxxxxxxx xxxxxxxxx 3 xxxxxxxxx xxxxx, bude xxxxxxx longitudinální profil Xxxxxxxxx xxx, že xxxx xxxxxxxxxx Xxxxxxxxxxxxxx xxxxxxxxxx v xxxxxxxxxxxxx 3 xxxxxxxx třikrát xxxxxxxx bez předchozího xxxxxxxx. Xxxxxxxx, který xxxxxxxxxx tuto xxxxxxxxxxxxxx xxxxxx, xxxx hlášen xxxx neobvyklý. Pokud xxxxxxxxxxxxxx profil Sportovce, xxxxxxxx xxxxxxxxxx xxxxx, xxxx xxxxxxxxxxxx xxxxxxxx, xxxx se xxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález.

X xxxxxxxx xxxxxxxx individuálních xxxxxxxxx může být x xxxx xxxxxx xxxxxxx boldenon endogenního xxxxxx ve velice xxxxxx xxxxxxxxxxxxx (xx/xx). Xxxxx xxxxxxxxx xxxxxx xxxxx xxxxxxxxx a xxxxxxx spolehlivé analytické xxxxxx (xxxx. XXXX) xxxxxxxxxxx xxxxxxxx xxxxx Xxxxxxxx xxxxx, xxxx xxx xxxxxxxxx xxxxx xxxxxxx xxxxxxxxxx xxxxxxxxxx xxxxx (xxxxxxxxxx xxxxx).

Xxxxx laboratoř nahlásila Xxxxxxxxx laboratorní nález 19-xxxxxxxxxxxxxxx, xxxx xx xx xxxxxxxxx za xxxxxxx x xxxxxxxxxxx xxxxx exogenního xxxxxx Xxxxxxxx xxxxx. X xxxxxxx xxxxxxx xxxx xxxxx xxxxxxxx xxxxx xxxxxxx.

X xxxxxxx, xx Xxxxxxxxx nebude xxxxxxxxxxxxx xxx xxxxxxx xxxxxxxxx, bude se xxx xx xx, xx Xxxxxx Xxxxxxxxx xxxxxxxx Xxxxxxxxx xxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX), tibolon, xxxxxxx, xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.

S2. XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx xxxxx x xxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxx:

1. Xxxxxxxxxxxx (EPO);

2. Xxxxxxx xxxxxx (xXX), xxxxxxxx xxxxxxx xxxxxxx xxxxxxx (xxxx. XXX-1), xxxxxxxxxx růstové xxxxxxx (MGF);

3. Xxxxxxxxxxxxx (např. LH, xXX), xxxxxxxx xxx x xxxx;

4. Xxxxxxxx;

5. Kortikotropiny

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

Xxxxx Xxxxxxxxx xxxxxx prokázat, xx xxxxxxxxxxx byla xxxxxxxxx fyziologickým xx xxxxxxxxxxxx stavem, bude xx xxx xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx látku (xxx je xxxxxxx xxxx) x xxxxxxxxx, xxx xxxxxxxxxxx Xxxxxxxx xxxxx nebo xxxxxx xxxxxxxxxx či xxxxxxxxxx x/xxxx příslušné xxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxx překročí xxxxxxx xxxxxxxx zjištěné x xxxx tak, xx xxxxxxxxxxxx xxxxxxxx xxxxxxxxx xxxxxxxx.

Pokud laboratoř xxxxxxxxx, xx xxxxx xxxxxxxxxx xxxxxxxxxx xxxxxx, xx Zakázaná látka xx xxxxxxxxxx xxxxxx, xxxx xx mít xx xx, že Xxxxxx xxxxxxxx Xxxxxxxxx xxxxx x xxxx xxxxxxx Pozitivní laboratorní xxxxx.

S3. XXXX-2 XXXXXXXX

Xxxxxxx xxxx-2 agonisté xxxxxx xxxxxx X- a X-xxxxxxx xxxx zakázáni.

Xxxxxxxx jsou xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxx, pro xxxxx xx při xxxxxxxx xxxxx xxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxx.

X xxxx xxxx xxxxxxx xxxxxxxx xxxxx terapeutické xxxxxxx, xxxx xxxxx xxxxxxxxxxx (xxxxx plus xxxxxxxxxx) xxxxx xxx 1000 nanogramů v 1 xxxxxxxxx xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxxxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx terapeutickým xxxxxxxx xxxxxxxxxxx v xxxxxxxx.

X4. ANTAGONISTÉ X XXXXXXXXXX XXXXXXX

Xxxxxxxxxxx xxxxxxx jsou xxxxxxxx:

1. Inhibitory xxxxxxxx, xxxxxxxxxx:

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SERM), xxxxxxxx:

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale ne x xxxxxxxx xxxxx xx xx.

X5. XXXXXXXXX X XXXXXXX MASKOVACÍ XXXXX

Xxxxxxxxx xxxxx xxxx zakázané. Zahrnují:

Xxxxxxxxx*, xxxxxxxxxxxxxx, probenecid, xxxxxxxxxx xxxx-xxxxxxxxx (xxxx. xxxxxxxxxx, dutasterid), xxxxxxxxxxxxxxx (xxxx. albumin, xxxxxxx, xxxxxxxxxxxxxxxxx) a xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, chlortalidon, xxxxxxxxx, xxxxxxxx, kyselina xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky (xxxxx xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx).

* Xxxxxxxxxxxx xxxxxxx xxxx xxxxxx, xxxxx xxx Sportovce xxxxxxxx diuretika xx xxxxxxx s xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxx Zakázané xxxxx (xxxxx).

X1. XXXXXXXXX PŘENOSU XXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2. XXXXXXXX X FYZIKÁLNÍ XXXXXXXXXX

M3. XXXXXX DOPING

Xxxxxxxxxxxxxx xxxxxxx xxxxx, xxxx, xxxxxxxx xxxxxxxx, nebo xxxxxxxxxx xxxxxxx xxxx, xxxxx xxxx xxxxxxxxx xxxxxx sportovní xxxxx, xx xxxxxxxx.

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx (včetně obou xxxxxx xxxxxxxxxx xxxxxxxxx (X- x L-) xxxxxxx) jsou xxxxxxxx, x xxxxxxxx xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxx x stimulancií zahrnutých xx Xxxxxxxxxxxxxx programu xxx xxx 2008.

Xxxxxxxxxxx xxxxxxxx:

Xxxxxxxxx, xxxxxxxxx**, xxxxxxxxxx, amfetaminil, xxxxxxxxxx, xxxxxxxxx, benzfetamin, xxxxxxxxxxxxxxx, xxxxxxxxx, cyklazodon, xxxxxxxxxxxxxxxxx, xxxxxxx****, etamivan, xxxxxxxxx, ethylamfetamin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, fenproporex, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, xxxxx***, xxxxxxxxxxx, kokain, xxxxxxxxxxx, krotetamid, levmetamfetamin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx (D-), xxxxxxxxxxxx****, xxxxxxxxxxxxxxxxxxxxxx, methylendioxymetamfetamin, xxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, niketamid, xxxxxxxxxxx, norfenfluramin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, p-methylamfetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxxxxxx neuvedené výslovně xxxx xxxxxxxx x xxxxx oddíle xxxx xxxxxxxxxx xx xxxxxxxxxxx xxxxx pouze, pokud Xxxxxxxxx prokáže, xx xxxx xxxxxxxxx dostupnost x běžných léčebných xxxxxxxxxxx xxxxxxxx neúmyslné xxxxxxxx xxxxxxxxxxxxxxx pravidel, xxxx xx x xxx xxxxx xxxxxxxxxxxxxxx, xx bude úspěšně xxxxxxxx xxxx dopingová xxxxx.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), fentanyl x xxxx xxxxxxxx, xxxxxxxxxxx, xxxxxxx, morfin, xxxxxxxx, oxymorfon, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Kanabinoidy (např. xxxxx, xxxxxxxxx) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx glukokortikosteroidy xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx nitrosvalovou xxxxxxxx xxxx xxxxxxxx. Xxxxxx xxxxx vyžaduje xxxxxxxxxxxxx xxxxxxx.

Jiné xxxxxxx injekční aplikace (xxxxxxxxxxxx, xx xxxxx xxxxxx, xx xxxxx xxxxxx, epidurální, xx xxxx) a inhalační xxxxxxxx xxxxxxxx zkrácenou xxxxxxxxxxxxx výjimku x xxxxxxxx xxxx xxxxxxxxx.

Xxxxxxx přípravky podávané xx xxxxxx kožní (xxxxxx xxxxxxxxxxx/xxxxxxxxxx), xxxx, xxxxx, xxxx, potíže xxxxx xxxxxxx xxxxxx, xxxxxxxx xxx x xxxxx xxxxxx xxxxxxxx x xxxxxxxxxx xxxxxx xxxxx terapeutické xxxxxxx.

X1. XXXXXXX

Xxxxxxx (etanol) xx zakázaný xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx bude provádět xxxxxxxx zkouškou x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx porušení xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je xxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxx.

∙ Xxxxxxxxxxxx xxxxx (FIA) (0.10 x/x)

∙ Xxxxxx (WKF) (0.10 x/x)

∙ Letecké xxxxxx a xxxxxxxxxxxx (XXX) (0.20 x/x)

∙ Xxxxxxxxxxx (XXXX, XXX) (0.10 x/x)

∙ Xxxxxxx pětiboj (XXXX) xxx xxx xxxxxxxxxx xx xxxxxxxx (0.10 x/x)

∙ Xxxxxxxxxxx sport (XXX) (0.10 x/x)

∙ Xxxxx xxxxxxxxxx (XXX) (0.30 x/x)

∙ Kuželky (IPC) (0.10 x/x)

X2. BETA-BLOKÁTORY

Xxxxx xxxx xxxxx určeno, xxxx-xxxxxxxxx jsou xxxxxxxx xxxxx Xxx xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.

∙ Automobilový xxxxx (XXX)

∙ Billiard (XXXX)

∙ Boby (XXXX)

∙ Bridž (XXX)

∙ Xxxxxxx (XXX)

∙ Xxxxxxxxxx (XXX)

∙ Xxxxxxxx (XXXX) - "xxxxx xxxx" - jen xxxxxxxxxxx

∙ Xxxxxxx (XXX)

∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx (XXX)

∙ Lukostřelba (XXXX, XXX) (xxxxxxxx xxxx Mimo soutěž)

∙ Xxxxxxxx (XXX) - xxxxx na xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx, x snowboard X-xxxxx x "xxx air"

∙ Moderní pětiboj (XXXX) - jen xxxxxxxxxx se střelbou

∙ Motocyklový sport (XXX)

∙ Xxxxxxxx x obdobné xxxxxx (XXXX, XXX "xxxxx")

∙ Xxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)

∙ Xxxxx motorismus (XXX)

∙ Xxxxx (XXXX)

Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:

Xxxxxxxxxx, alprenolol, xxxxxxxx, betaxolol, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, sotalol, xxxxxxx, xxx xx s xxxxxxxx xxxxx xx xx

"Specifické xxxxx"* xxxx xxxxxxxxxxx níže:

∙ Všichni Xxxx-2 xxxxxxxx x xxxxxxxx, xxxxx xxxxxxxxxxx (xxxxxxx xxxx xxxxxxxxxxx) xxx xxxxxxxx větším xxx 1000 ng/ml moči x clenbuterolu (xxxxxxx xx xxxxxxx X 1.2 Xxxxxxx xxxxxxxxxx xxxxx);

∙ Xxxxxxxxxx xxxx-xxxxxxxxx, xxxxxxxxxx;

∙ Xxxxx, kropropamid, xxxxxxxxxx, xxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, haptaminol, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, x-xxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, ortetamin, xxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx x všechna xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxxxxxx x xxxxxx X6, xxx která Xxxxxxxxx xxxxxxx, xx xxxxxxx podmínky xxxxxxx x xxxxxx X6;

∙ Xxxxxxxxxxx;

∙ Xxxxxxx Glukokortikosteroidy;

∙ Xxxxxxx;

∙ Xxxxxxx Xxxx-xxxxxxxxx.

*"V Xxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxxxxx xxxxx, xxxxx xxxxxxxx umožňuji neúmyslné xxxxxxxx antidopingových xxxxxxxx, xxxxxxx jsou xxxxxxxxx xxxxxxxx x xxxxxxx xxxxxxxxx xxxxxxxxxxx, xxxx x xxxxx xx xxxxx xxxxxxxxxxxxxxx, že xxxxx xxxxxxx zneužity xxxx dopingová činidla." Xxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx takovéto látky xxxx xxxxxxxx snížený xxxxxx za předpokladu, xx "...Sportovec xxxx xxxxx prokázat, že Xxxxxxx specifické xxxxx xxxxxx xxxxxxxxx xx xxxxxxx sportovního xxxxxx...".

Xxxxxx předpis x. 2/2008 Sb. x. x. xxxxx xxxxxxxxx xxxx 31.1.2008.

Xxxxxx xxxxxxx č. 2/2008 Xx. m. x. xxx zrušen xxxxxxx xxxxxxxxx č. 8/2009 Sb. m. s. x účinností od 7.2.2009.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, pokud xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.